<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Promis Neurosciences Inc. — News on 6ix</title>
<link>https://6ix.com/company/promis-neurosciences-inc</link>
<description>Latest news and press releases for Promis Neurosciences Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 13 Apr 2026 11:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/promis-neurosciences-inc" rel="self" type="application/rss+xml" />
<item>
<title>ProMIS Neurosciences Invited to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference</title>
<link>https://6ix.com/company/promis-neurosciences-inc/news/promis-neurosciences-invited-to-participate-in-the-2026-bloom-burton-and-co-healthcare-investor-conference</link>
<guid isPermaLink="true">https://6ix.com/company/promis-neurosciences-inc/news/promis-neurosciences-invited-to-participate-in-the-2026-bloom-burton-and-co-healthcare-investor-conference</guid>
<pubDate>Mon, 13 Apr 2026 11:30:00 GMT</pubDate>
<description>Cambridge, Massachusetts--(Newsfile Corp. - April 13, 2026) - ProMIS Neurosciences, Inc. (NASDAQ: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other neurodegenerative disorders, today announced that Neil Warma, Chief Executive Officer, will participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference. The conference is being held April 21-22, 2026, at the Metro Toronto Convention Centre in Toronto, Ontario. ...</description>
</item>
<item>
<title>ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights</title>
<link>https://6ix.com/company/promis-neurosciences-inc/news/promis-neurosciences-announces-full-year-2025-financial-results-and-provides-corporate-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/promis-neurosciences-inc/news/promis-neurosciences-announces-full-year-2025-financial-results-and-provides-corporate-highlights</guid>
<pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
<description>PRECISE-AD Phase 1b trial fully enrolled. Completion of six-month assessments expected in Q2 2026 with blinded interim analysis anticipated early Q3 2026;</description>
</item>
<item>
<title>ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer’s Disease/Parkinson’s Disease 2026 International Conference (AD/PD™)</title>
<link>https://6ix.com/company/promis-neurosciences-inc/news/promis-neurosciences-to-present-data-on-als-and-parkinsons-disease-programs-at-alzheimers-diseaseparkinsons-disease-2026-international-conference-adpdtm</link>
<guid isPermaLink="true">https://6ix.com/company/promis-neurosciences-inc/news/promis-neurosciences-to-present-data-on-als-and-parkinsons-disease-programs-at-alzheimers-diseaseparkinsons-disease-2026-international-conference-adpdtm</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>Cambridge, Massachusetts, March 18, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing</description>
</item>
<item>
<title>ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026</title>
<link>https://6ix.com/company/promis-neurosciences-inc/news/promis-neurosciences-participate-guggenheim-emerging-210500972</link>
<guid isPermaLink="true">https://6ix.com/company/promis-neurosciences-inc/news/promis-neurosciences-participate-guggenheim-emerging-210500972</guid>
<pubDate>Wed, 04 Feb 2026 21:05:00 GMT</pubDate>
<description>Cambridge, Massachusetts, Feb. 04, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced the company will be participating in a fireside chat and investor one-on-one meetings at the Guggenheim Emerging Outlook: Biotech Summit 2026 being held from February 11-12th, 2026 in New York, NY. The fireside chat will be held at 9:30am</description>
</item>
<item>
<title>ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing</title>
<link>https://6ix.com/company/promis-neurosciences-inc/news/promis-neurosciences-announces-175-million-130000464</link>
<guid isPermaLink="true">https://6ix.com/company/promis-neurosciences-inc/news/promis-neurosciences-announces-175-million-130000464</guid>
<pubDate>Fri, 30 Jan 2026 13:00:00 GMT</pubDate>
<description>Extends cash runway into 2028 Proceeds expected to enable completion of ProMIS’ landmark Phase 1b AD study and support execution of key clinical milestones Blinded 6-month top-line data expected mid-2026; 12-month top-line data expected toward end of 2026 CAMBRIDGE, Massachusetts , Jan. 30, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (“ProMIS” or the “Company”), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics and vacc</description>
</item>
<item>
<title>ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease</title>
<link>https://6ix.com/company/promis-neurosciences-inc/news/promis-neurosciences-exceeds-target-enrollment-123000150</link>
<guid isPermaLink="true">https://6ix.com/company/promis-neurosciences-inc/news/promis-neurosciences-exceeds-target-enrollment-123000150</guid>
<pubDate>Thu, 18 Dec 2025 12:30:00 GMT</pubDate>
<description>Large, well-powered Phase 1b study, designed to generate clinically and biologically meaningful insights in early Alzheimer’s disease Clear and near-term value inflection points, with blinded 6-month interim data expected in Q2 2026 and final unblinded top-line results anticipated in Q4 2026 CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics and vacc</description>
</item>
<item>
<title>ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk</title>
<link>https://6ix.com/company/promis-neurosciences-inc/news/promis-neurosciences-announces-peer-reviewed-123000149</link>
<guid isPermaLink="true">https://6ix.com/company/promis-neurosciences-inc/news/promis-neurosciences-announces-peer-reviewed-123000149</guid>
<pubDate>Wed, 10 Dec 2025 12:30:00 GMT</pubDate>
<description>Results support the potential of PMN310 to improve outcomes by selectively targeting oligomers and avoiding binding to monomer and plaque ProMIS on track to complete enrollment in PRECISE-AD trial in Alzheimer’s disease by end of 2025 with planned Q2 2026 interim readout Cambridge, Massachusetts, Dec. 10, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics and vaccines targetin</description>
</item>
<item>
<title>ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310</title>
<link>https://6ix.com/company/promis-neurosciences-inc/news/promis-neurosciences-announces-peer-reviewed-123000110</link>
<guid isPermaLink="true">https://6ix.com/company/promis-neurosciences-inc/news/promis-neurosciences-announces-peer-reviewed-123000110</guid>
<pubDate>Mon, 01 Dec 2025 12:30:00 GMT</pubDate>
<description>Cross-trial analysis supports plasma pTau as a potential early predictor of clinical benefit, reinforcing the biomarker-driven design of ProMIS’ PRECISE-AD trial ProMIS on track to leverage new plasma pTau insights with planned Q2 2026 interim readout Cambridge, Massachusetts, Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics and vaccines targeting toxic misfolded pr</description>
</item>
<item>
<title>ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference</title>
<link>https://6ix.com/company/promis-neurosciences-inc/news/promis-neurosciences-participate-8th-annual-120000183</link>
<guid isPermaLink="true">https://6ix.com/company/promis-neurosciences-inc/news/promis-neurosciences-participate-8th-annual-120000183</guid>
<pubDate>Mon, 01 Dec 2025 12:00:00 GMT</pubDate>
<description>Cambridge, Massachusetts, Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will be participating in a fireside chat and investor one-on-one meetings at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2nd, 2025. The fireside chat</description>
</item>
<item>
<title>ProMIS Neurosciences Announces Reverse Stock Split</title>
<link>https://6ix.com/company/promis-neurosciences-inc/news/promis-neurosciences-announces-reverse-stock-130000303</link>
<guid isPermaLink="true">https://6ix.com/company/promis-neurosciences-inc/news/promis-neurosciences-announces-reverse-stock-130000303</guid>
<pubDate>Mon, 24 Nov 2025 13:00:00 GMT</pubDate>
<description>Cambridge, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced that its board of directors has determined to effect a one-for-twenty-five reverse stock split of the Company’s common shares, no par value per share (Common Shares). The reverse stock split will take effect at 12:01 a.m. Eastern Time on November</description>
</item>
<item>
<title>ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights</title>
<link>https://6ix.com/company/promis-neurosciences-inc/news/promis-neurosciences-announces-third-quarter-120000211</link>
<guid isPermaLink="true">https://6ix.com/company/promis-neurosciences-inc/news/promis-neurosciences-announces-third-quarter-120000211</guid>
<pubDate>Wed, 12 Nov 2025 12:00:00 GMT</pubDate>
<description>Phase 1b trial in Alzheimer’s disease is over 85% enrolled: Cohorts 1 and 2 are fully enrolledPMN310 continues to demonstrate a favorable safety profileOn track to report 6-month interim data in Q2 2026 and final 12-month top-line results in Q4 2026 Cambridge, Massachusetts, Nov. 12, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neuro</description>
</item>
<item>
<title>ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference</title>
<link>https://6ix.com/company/promis-neurosciences-inc/news/promis-neurosciences-participate-guggenheim-2nd-210500731</link>
<guid isPermaLink="true">https://6ix.com/company/promis-neurosciences-inc/news/promis-neurosciences-participate-guggenheim-2nd-210500731</guid>
<pubDate>Mon, 03 Nov 2025 21:05:00 GMT</pubDate>
<description>Cambridge, Massachusetts, Nov. 03, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, and members of senior management will be participating in a fireside chat and investor one-on-one meetings at the Guggenheim 2nd Annual Healthcare Innovation Conference on</description>
</item>
<item>
<title>ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group</title>
<link>https://6ix.com/company/promis-neurosciences-inc/news/promis-neurosciences-strengthens-board-appointment-113000329</link>
<guid isPermaLink="true">https://6ix.com/company/promis-neurosciences-inc/news/promis-neurosciences-strengthens-board-appointment-113000329</guid>
<pubDate>Wed, 22 Oct 2025 11:30:00 GMT</pubDate>
<description>Appointment reinforces ProMIS Neurosciences’ strategic vision and deepens investor engagement as the Company advances its differentiated Alzheimer’s program, PMN310 Cambridge, Massachusetts, Oct. 22, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced that Slanix Paul Alex, Pharm.D., President and Portfolio Manager for Ally</description>
</item>
<item>
<title>ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310</title>
<link>https://6ix.com/company/promis-neurosciences-inc/news/promis-neurosciences-receives-dsmb-approval-110000009</link>
<guid isPermaLink="true">https://6ix.com/company/promis-neurosciences-inc/news/promis-neurosciences-receives-dsmb-approval-110000009</guid>
<pubDate>Wed, 03 Sep 2025 11:00:00 GMT</pubDate>
<description>Cohort 2 fully enrolled; enrollment and dosing now underway for Cohort 3 (final dose level); No cases of amyloid-related imaging abnormalities (ARIA) observed to date; The trial, expected to enroll 128 patients, remains on track to report 6-month interim data in Q2 2026 and final 12-month top-line results in Q4 2026. Cambridge, Massachusetts, Sept. 03, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies fo</description>
</item>
<item>
<title>ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights</title>
<link>https://6ix.com/company/promis-neurosciences-inc/news/promis-neurosciences-announces-second-quarter-110000157</link>
<guid isPermaLink="true">https://6ix.com/company/promis-neurosciences-inc/news/promis-neurosciences-announces-second-quarter-110000157</guid>
<pubDate>Wed, 13 Aug 2025 11:00:00 GMT</pubDate>
<description>U.S. FDA Grants Fast Track Designation for PMN310 in Alzheimer’s Disease, enhancing program’s potential for priority review PRECISE-AD Phase 1b Trial in Alzheimer’s Disease Progressing on Schedule: Over 50% enrolled, no cases of ARIA and no patient dropouts to date Strengthened Financial Position with $21.6 Million in Gross Proceeds Raised in July 2025 Cambridge, Massachusetts, Aug. 13, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focus</description>
</item>
<item>
<title>ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer’s Association International Conference</title>
<link>https://6ix.com/company/promis-neurosciences-inc/news/promis-neurosciences-showcase-protein-misfolding-120000849</link>
<guid isPermaLink="true">https://6ix.com/company/promis-neurosciences-inc/news/promis-neurosciences-showcase-protein-misfolding-120000849</guid>
<pubDate>Tue, 29 Jul 2025 12:00:00 GMT</pubDate>
<description>Presentation to highlight the Company’s proprietary protein-misfolding platform, EpiSelectTM, used to develop PMN310 Posters highlighting PRECISE-AD, the Company’s Phase 1b clinical trial design and optimization of biomarkers in AD Progress with trial enrollment following DSMB recommendation to proceed to second dose level CAMBRIDGE, Massachusetts , July 29, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to the discovery and dev</description>
</item>
<item>
<title>ProMIS Neurosciences Announces Private Placement Financing</title>
<link>https://6ix.com/company/promis-neurosciences-inc/news/promis-neurosciences-announces-private-placement-110000017</link>
<guid isPermaLink="true">https://6ix.com/company/promis-neurosciences-inc/news/promis-neurosciences-announces-private-placement-110000017</guid>
<pubDate>Mon, 28 Jul 2025 11:00:00 GMT</pubDate>
<description>$3 million private financing plus an additional $9 million of proceeds due to exercise of warrants, for gross proceeds of approximately $12.0 millionTORONTO, Ontario and CAMBRIDGE, Massachusetts, July 28, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to discovery and development of therapeutic antibodies targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzhiemer’s disease (AD), amyotrophic lateral scle</description>
</item>
<item>
<title>ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/promis-neurosciences-inc/news/promis-neurosciences-announces-0-8-110000286</link>
<guid isPermaLink="true">https://6ix.com/company/promis-neurosciences-inc/news/promis-neurosciences-announces-0-8-110000286</guid>
<pubDate>Tue, 22 Jul 2025 11:00:00 GMT</pubDate>
<description>CAMBRIDGE, Massachusetts, July 22, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to discovery and development of therapeutic antibodies targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzhiemer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD), today announced that it has raised $0.8 million at-the-market from an existing healthcare focused institutional investor. The com</description>
</item>
<item>
<title>ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer’s Disease</title>
<link>https://6ix.com/company/promis-neurosciences-inc/news/promis-neurosciences-granted-fast-track-120000610</link>
<guid isPermaLink="true">https://6ix.com/company/promis-neurosciences-inc/news/promis-neurosciences-granted-fast-track-120000610</guid>
<pubDate>Mon, 21 Jul 2025 12:00:00 GMT</pubDate>
<description>FDA designation highlights the potential of PMN310 to deliver a more targeted approach to treating Alzheimer’s DiseaseCAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD), today announced</description>
</item>
<item>
<title>ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference</title>
<link>https://6ix.com/company/promis-neurosciences-inc/news/promis-neurosciences-presents-h-c-110000794</link>
<guid isPermaLink="true">https://6ix.com/company/promis-neurosciences-inc/news/promis-neurosciences-presents-h-c-110000794</guid>
<pubDate>Tue, 17 Jun 2025 11:00:00 GMT</pubDate>
<description>Webcast of virtual fireside chat today, June 17th, at 7:00 a.m. ETCAMBRIDGE, Massachusetts, June 17, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies selective for toxic oligomers associated with the development and progression of neurodegenerative diseases such as Alzheimer’s Disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), as well as o</description>
</item>
</channel>
</rss>